On December 16, NPWH participated in the monthly Department of Health & Human Services (HHS) Provider Roundtable. Dr. Debra Houry, Director, National Center for Injury Prevention and Control, CDC, spoke about the draft CDC Opioid Prescribing Guidelines. The guidelines provide suggested direction on a number of topics, including discussing risks and benefits with patients, nonpharmacological therapies, and duration of treatment. The draft guidelines are posted on the federal register and open for public comment from Dec. 14, 2015-Jan. 13, 2016. The CDC is looking for feedback and comments from providers of special populations (e.g. pregnant patients). We encourage to take a look at the draft guidelines and provide comments/feedback. The HHS Pharmaceutical Forum and the open enrollment deadline extension were also discussed during the meeting.
On December 15, Congress released a long awaited budget deal which will fund the government through FY16. Women’s groups expected the deal to contain policy riders which would be seriously harmful to the health of women and their families. Surprisingly, the bill does not contain harmful policy riders and maintains current funding levels for important preventative women’s health programs, including the PALS Act. Read the statement from NPWH and other women’s health care organizations regarding our support and applause for Congress’ protection of women’s access to mammograms.
Read more about the spending bill here.
On Thursday, December 3, NPWH along with 15 stakeholders attended the meeting, including American Academy of Pediatrics, American Congress of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, Society for Women’s Health Research, and Association of Women’s Health, Obstetric and Neonatal Nurses, American College of Nurse Midwives attended the Coalition to Advance Maternal Therapeutics Stakeholder Meeting.
The meeting focused on the new FDA pregnancy and lactation labeling rule with a history of pregnancy labeling, problems with the old system, processes used to develop new labeling rule, and examples of the requirements of the new labeling rule. The CDC presented on the Treating for Two initiative, the magnitude of medication use in pregnancy, and the objectives of the program. The objectives of Treating for Two include:
- Reduce fetal exposure to tetratogenic medications,
- Prevent birth defects and other adverse pregnancy outcomes,
- Improve women’s health by informing safe and effective treatment of conditions during pregnancy and the reproductive years
- Increase confidence in using medications during pregnancy that are not associated with adverse outcomes
Learn more about the Treating for Two initiative here.